L1000-CDS2 predicted that small molecule drugs such as histone deacetylase (HDAC) inhibitors might be a potential candidate to reverse the pathological gene expression signature in FECD. This evidence concerns the gene HDAC9 and Fuchs endothelial corneal dystrophy.